Depreotide Scanning in Sarcoidosis: ACE level

Depreotide Scanning in Sarcoidosis: ACE levelThere was a strong correlation between the stage determined by CXR and that determined by 99mTc-DP scan. Based on the stage determined by the CXR obtained when the subject initially received a diagnosis, the interstudy agreement was high (к = 0.79; p = 0.0005). There was perfect concordance in 17 subjects (77.3%) as to the stage determined by both CXR and 99mTc-DP scan. When restricted to patients who had abnormal CXR findings at the time of 99mTc-DP image acquisition, the interstudy agreement was stronger (к = 0.94; p = 0.0001). In this instance, 99mTc-DP scanning “mis-staged” only one subject and revealed activity in the lung parenchyma when the lung fields were seen as being clear on the CXR. Comparing the CXRs that had been performed contemporaneously with the nuclear scans (as opposed to ones performed at the time of the initial diagnosis) to the 99mTc-DP scan results revealed an overall agreement in 95.5% of subjects. natural breast enhancement pill
As shown in Table 2, evidence of parenchymal activity on 99mTc-DP scans (11 patients) was associated with worse pulmonary function. Patients with positive parenchymal 99mTc-DP scan findings had a mean FVC of 68.6 ± 13.9% compared to 84.5 ± 10.7% in patients who lacking parenchymal activity (p = 0.012). Those with parenchymal uptake were 20.3 times (95% CI, 2.3 to 176.8) more likely to have an abnormal FVC (eg, below the predicted 95% CI). Similar results were seen in terms of the FEV1 with a mean FEV1 of 74.0 ± 16.0% in persons with positive parenchymal scans as opposed to 88.4 ± 12.7% among those with no 99mTc-DP activity in the lung tissue. Neither the Dlco nor the Dlco corrected for alveolar volume differed based on the status of the parenchyma as determined by 99mTc-DP imaging. However, measured as a categoric variable, all persons with evidence of 99mTc-DP activity in the parenchyma had abnormally low Dlco values compared to only 54.5% of individuals with normal parenchyma seen on 99mTc-DP scintigraphy (p = 0.035). The serum markers of inflammation were normal in nearly all patients and also did not differ based on the findings of 99mTc-DP scintigraphy. Specifically, the ACE level was elevated in seven subjects. The mean ACE level was 45.9 ± 27.0 U/L in those without activity on 99mTc-DP scans, while it was 41.0 ± 34.7 U/L in those with normal scintigraphy findings (difference was not significant).
Table 2—PFTs and Parenchymal Activity

Variables 99mTc-DP Findings, % predicted p Value
IParenchyma + IParenchyma —
FVC 68.6 ± 13.9 84.5 ± 10.7 0.012
FEVj 74.0 ± 16.0 88.4 ± 12.7 0.041
Dlco 63.0 ± 17.2 69.8 ± 10.4 NS
DL/VA 82.3 ± 9.3 84.2 ± 10.2 NS
This entry was posted in Sarcoidosis and tagged depreotide, gallium, nuclear imaging, sarcoidosis, somatostatin, stage.